To study the possible role of complement factor mutations in patients with Tubercular Serpiginous-like choroiditis
Implementing Organization
Department of Biochemistry, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012
Principal Investigator
Prof. Reema Bansal
Post Graduate Institute Of Medical Education And Research (PGIMER), Chandigarh
CO-Principal Investigator
Dr. Prateek Bhatia
Post Graduate Institute Of Medical Education And Research (PGIMER), Chandigarh-160012, Prof. Vishali Gupta, Post Graduate Institute Of Medical Education And Research (PGIMER), Chandigarh-160012, Dr. Basavaraj Tigari, Post Graduate Institute Of Medical Education And Research (PGIMER), Chandigarh-160012
Project Overview
The study aims to investigate the possible association of complement system gene variations with tubercular Serpiginous-like Choroiditis (SLC), a manifestation of ocular tuberculosis (TB), which causes sight-threatening uveitis. SLC shares clinical and pathophysiologic features with AMD, MFC, and ocular sarcoidosis, suggesting a common genetic basis for these diseases. Clinical heterogeneity, racial/geographic variations, and varying treatment outcomes in SLC also suggest an unidentified genetic susceptibility in the hosts. SLC affects the retinal pigment epithelium (RPE) and choroid, and RPE cells synthesize and express CFH, complement factor B (CFB), and C2. The study hypothesizes that CFH, CFB, and C2 may contribute to the pathogenesis of SLC. The research will involve enrolment of 30 SLC cases, 30 TB uveitis cases without SLC, and 90 healthy controls. The work flow will include blood sample collection, DNA isolation and storage, NGS run, and bioinformatics analysis. The findings will help in counseling patients with widespread retinal/choroidal damage and reveal the genetic basis of SLC. Elucidation of the complement playing a role in SLC could make it a potential therapeutic target. Depending on the pathways involved, selective components of the complement cascade (initiators, regulators, or effectors) can be targeted to develop complement-targeted drugs to minimize or eliminate the severe visual loss accompanying SLC.
Source
Source
Science and Engineering Research Board (SERB), DST 2022-23
Science and Engineering Research Board (SERB), New Delhi
Quick Information
Area of Research
Life Sciences & Biotechnology
Start Date
2022
End Date
2025
Status
Completed
Contact
drreemab@rediffmail.com
Output
No. of Research Paper
00
Technologies (If Any)
00
No. of PhD Produced
00
Publications
00
No. of Patents
Filed :00
Grant :00
Disclaimer:
Information available on this portal is sourced from various organizations and is provided for informational purposes only. Users are advised to verify details from the respective official sources.
Please enter your details
Please provide your name and email to continue. Your details are saved in this browser for future use.
Latest Updates
Loading…
⚠️
You are leaving this website
You are about to be redirected to an external website that is not operated by
India Science, Technology & Innovation (ISTI) Portal.